Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.
Jens Kuhle, MD, PhD
Advertisement
Head, MS Center, and Senior Physician, University Hospital Basel
Articles by Jens Kuhle, MD, PhD
The senior physician and head of the Multiple Sclerosis Centre at University Hospital Basel spoke about his partnership with Octave and their work assessing and validating biomarkers for use in multiple sclerosis. [WATCH TIME: 4 minutes]
The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
The Role of Biomarkers in Multiple SclerosisMarch 4th 2024
Expanding the Biomarker Panel in MS: Jens Kuhle, MD, PhDDecember 1st 2022
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease
2
FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea
3
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
4
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3
5